Welcome to Paid Research Studies


Browse Locations ... United States» ... Delaware» ... Bear





  • Condition:   Preterm Birth
    Intervention:   Other: Screened Arm
    Sponsor:   Christiana Care Health Services
    Not yet recruiting - verified April 2017

  • Condition:   Anti-Mullerian Hormone
    Intervention:   Diagnostic Test: Access AMH Assay
    Sponsor:   Beckman Coulter, Inc.
    Recruiting - verified April 2017

  • Condition:   Advanced Solid Malignancies
    Interventions:   Biological: MEDI4736 (Durvalumab);   Biological: MEDI4736 (Durvalumab) + Tremelimumab
    Sponsor:   AstraZeneca
    Recruiting - verified May 2017

  • Condition:   Low Back Pain
    Interventions:   Behavioral: SFEX+H;   Behavioral: SFEX
    Sponsor:   University of Delaware
    Recruiting - verified May 2017

  • Condition:   Analgesia
    Interventions:   Drug: HTX-011;   Drug: Saline Placebo;   Drug: Bupivicaine HCl
    Sponsor:   Heron Therapeutics
    Recruiting - verified May 2017

  • Condition:   Diabetes Mellitus Type 2
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting - verified May 2017

  • Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Atezolizumab;   Drug: Daratumumab
    Sponsors:   Janssen Research & Development, LLC;   Genentech, Inc.
    Recruiting - verified April 2017

  • Condition:   Cholangiocarcinoma
    Intervention:   Drug: INCB054828
    Sponsor:   Incyte Corporation
    Recruiting - verified May 2017

  • Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer;   Stage III Rectal Cancer
    Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
    Interventions:   Drug: Fluorouracil;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Nicotine Dependence
    Interventions:   Behavioral: Sleep Advancement Counseling;   Behavioral: General Health Information
    Sponsor:   University of Delaware
    Recruiting - verified October 2016

  • Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Heart Failure;   Chronic Heart Failure With Reduced Ejection Fraction
    Interventions:   Drug: Vericiguat;   Drug: Placebo for Vericiguat
    Sponsors:   Merck Sharp & Dohme Corp.;   Bayer;   Canadian VIGOUR Centre;   Duke Clinical Research Institute
    Recruiting - verified May 2017

  • Condition:   Stroke
    Interventions:   Behavioral: FAST;   Behavioral: FAST+SAM;   Behavioral: SAM
    Sponsors:   University of Delaware;   University of Pennsylvania;   Christiana Care Health Services
    Recruiting - verified May 2017

  • Condition:   Veno-occlusive Disease
    Interventions:   Drug: Defibrotide;   Other: Best Supportive Care
    Sponsor:   Jazz Pharmaceuticals
    Recruiting - verified April 2017

  • Conditions:   Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Dermoid Cyst;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Opioid Induced Constipation
    Interventions:   Drug: naloxegol;   Drug: non-PAMORA
    Sponsor:   AstraZeneca
    Recruiting - verified May 2017

  • Condition:   Urothelial Carcinoma
    Interventions:   Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Gemcitabine;   Other: Placebo;   Drug: Cisplatin
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified April 2017

  • Condition:   Alzheimer's Disease
    Interventions:   Drug: LY3202626;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified May 2017

  • Conditions:   Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2017

  • Condition:   Non-small Cell Lung Cancer
    Interventions:   Biological: Pembrolizumab;   Drug: Paclitaxel;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Drug: Saline placebo for pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified April 2017

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Olokizumab 64mg q4w;   Drug: Olokizumab 64mg q2w;   Drug: Adalimumab 40mg q2w;   Drug: Placebo q2w
    Sponsors:   R-Pharm;   Quintiles, Inc.;   OCT Clinical Trials
    Recruiting - verified May 2017

  • Condition:   Colorectal Cancer
    Interventions:   Drug: Napabucasin;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Irinotecan;   Drug: Bevacizumab
    Sponsor:   Boston Biomedical, Inc
    Recruiting - verified May 2017

  • Condition:   Lyme Disease
    Intervention:   Device: Borrelia Diagnostic Test
    Sponsor:   Advanced Laboratory Services, Inc.
    Recruiting - verified May 2017

  • Condition:   Pain, Postoperative
    Interventions:   Drug: Gabapentin;   Drug: Acetaminophen;   Drug: Celecoxib
    Sponsor:   Christiana Care Health Services
    Recruiting - verified May 2017

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Incyte Corporation;   Children's Oncology Group
    Recruiting - verified May 2017

  • Condition:   Severe Complications of Urinary Tract Infections
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting - verified May 2017

  • Condition:   Acute Liver Injury
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting - verified May 2017

  • Condition:   Acute Kidney Injury
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting - verified May 2017

  • Conditions:   Breast Cancer;   Bladder Cancer
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting - verified May 2017

  • Condition:   Heart Failure
    Interventions:   Drug: Iobenguane I -123 Injection;   Device: Implantable Cardioverter Defibrillator;   Drug: Thyroid blocking
    Sponsors:   GE Healthcare;   TFS Trial Form Support;   ICON plc
    Recruiting - verified May 2017

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: ABT-494;   Drug: Placebo for ABT-494;   Drug: Adalimumab;   Drug: Placebo for Adalimumab
    Sponsor:   AbbVie
    Recruiting - verified May 2017

  • Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Biological: Obinutuzumab;   Biological: Ublituximab;   Drug: TGR-1202;   Drug: Chlorambucil
    Sponsor:   TG Therapeutics, Inc.
    Recruiting - verified May 2017

  • Condition:   Osteoarthritis
    Intervention:   Drug: Investigational Medical Product (IMP) administered in parent study
    Sponsors:   Pfizer;   Eli Lilly and Company
    Recruiting - verified May 2017

  • Conditions:   High Grade Sarcoma;   Metastatic Leiomyosarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Myxofibrosarcoma;   Recurrent Leiomyosarcoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Synovial Sarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Uterine Corpus Leiomyosarcoma
    Interventions:   Drug: Pazopanib Hydrochloride;   Drug: Sapanisertib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Breast Carcinoma Metastatic in the Brain;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Stage IB Non-Small Cell Lung Carcinoma;   Stage II Non-Small Cell Lung Cancer;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
    Intervention:   Drug: Entrectinib
    Sponsor:   Ignyta, Inc.
    Recruiting - verified May 2017

  • Condition:   Inflammatory Bowel Diseases
    Intervention:   Drug: Infliximab
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting - verified May 2017

  • Conditions:   Glioblastoma;   Gliosarcoma
    Interventions:   Drug: ABT-414;   Radiation: Radiation;   Drug: Temozolomide;   Drug: Placebo for ABT-414
    Sponsors:   AbbVie;   Radiation Therapy Oncology Group
    Recruiting - verified May 2017

  • Condition:   Leukemia, Myeloid
    Intervention:   Drug: Lenalidomide
    Sponsor:   Celgene
    Recruiting - verified April 2017

  • Conditions:   Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Melanoma of the Skin;   Recurrent Non-Cutaneous Melanoma;   Stage III Mucosal Melanoma of the Head and Neck AJCC v7;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma;   Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Chronic Pain;   Osteoarthritis, Hip;   Osteoarthritis, Knee
    Interventions:   Drug: NSAID;   Biological: Tanezumab 2.5 mg;   Biological: Tanezumab 5 mg
    Sponsor:   Pfizer
    Recruiting - verified May 2017

  • Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Peripheral Artery Disease
    Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
    Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
    Recruiting - verified May 2017

  • Condition:   Malignant Neoplasm
    Intervention:   Other: Cytology Specimen Collection Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer;   Stage II Cervical Cancer;   Stage II Vaginal Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Vaginal Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Vaginal Cancer;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Advanced Malignant Solid Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Necrotizing Soft Tissue Infections;   Necrotizing Fasciitis;   Fournier's Gangrene
    Interventions:   Drug: AB103 0.5 mg/kg;   Other: NaCl 0.9%
    Sponsors:   Atox Bio Ltd;   Biomedical Advanced Research and Development Authority
    Recruiting - verified May 2017

  • Condition:   Super-Refractory Status Epilepticus
    Interventions:   Drug: SAGE-547;   Drug: Placebo
    Sponsor:   Sage Therapeutics
    Recruiting - verified April 2017

  • Conditions:   Activated B-Cell-Like Diffuse Large B-Cell Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Endometrial Undifferentiated Carcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   AstraZeneca
    Recruiting - verified May 2017

  • Condition:   Heterozygous Familial Hypercholesterolemia
    Interventions:   Drug: Evolocumab;   Drug: Placebo
    Sponsor:   Amgen
    Recruiting - verified May 2017

  • Conditions:   Cognitive Impairment;   Metastatic Malignant Neoplasm in the Brain;   Solid Neoplasm
    Interventions:   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Memantine Hydrochloride;   Other: Quality-of-Life Assessment;   Radiation: Whole-Brain Radiotherapy;   Radiation: Whole-Brain Radiotherapy
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Osteogenesis Imperfecta
    Intervention:   Drug: Denosumab
    Sponsor:   Amgen
    Recruiting - verified May 2017

  • Condition:   Hypotension
    Intervention:   Drug: Phenylephrine
    Sponsor:   West-Ward Pharmaceutical
    Recruiting - verified May 2017

  • Condition:   CD33 Positive Acute Myelogenous Leukemia
    Intervention:   Biological: Antibody Drug Conjugate Chemotherapeutic
    Sponsor:   Pfizer
    Available - verified May 2017

  • Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Malignant Neoplasm
    Intervention:   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   BRAF NP_004324.2:p.V600X;   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
    Interventions:   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Adult Fibrosarcoma;   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
    Interventions:   Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Pulmonary Arterial Hypertension
    Intervention:   Drug: Opsumit (macitentan)
    Sponsor:   Actelion
    Recruiting - verified April 2017

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
    Interventions:   Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
    Sponsors:   Janssen Research & Development, LLC;   Bayer
    Recruiting - verified May 2017

  • Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
    Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Legg Calve Perthes Disease
    Interventions:   Procedure: osteotomy;   Procedure: multiple epiphyseal drilling
    Sponsors:   Texas Scottish Rite Hospital for Children;   Alberta Children's Hospital;   Alfred I. duPont Hospital for Children;   Le Bonheur Children's Hospital;   Children's Hospital Colorado;   Children's Hospital Los Angeles;   Children's Research Institute;   Children's Healthcare of Atlanta;   Children's Hospital of Philadelphia;   Children's Hospital Medical Center, Cincinnati;   Columbia University;   Connecticut Children's Medical Center;   Gillette Children's Specialty Healthcare;   Boston Children’s Hospital;   Johns Hopkins University;   Kaiser Permanente;   Kasturba Medical College;   Mayo Clinic;   Medical Universtity of Lodz;   Montefiore Medical Center;   Nationwide Children's Hospital;   New York University Langone Medical Center;   OrthoCarolina Research Institute, Inc.;   University of Sao Paulo General Hospital;   Seoul National University Childrens Hospital;   Shriners Hospitals for Children;   University Hospital Southampton NHS Foundation Trust;   Texas Children's Hospital;   Phoenix Children's Hospital;   University Hospital, Clermont-Ferrand;   Universitätsklinikum Hamburg-Eppendorf;   Sheffield Children's NHS Foundation Trust;   Royal Children's Hospital
    Recruiting - verified April 2017

  • Condition:   Nephrotic Syndrome
    Intervention:   Drug: ACTH
    Sponsors:   Emory University;   Mallinckrodt
    Recruiting - verified April 2017

  • Condition:   Primary Amenorrhea With Hypogonadotropic Hypogonadism
    Interventions:   Drug: Gonadorelin acetate 10µg/pulse;   Drug: Gonadorelin acetate 15µg/pulse;   Drug: Gonadorelin acetate 20µg/pulse;   Drug: Placebo
    Sponsor:   Ferring Pharmaceuticals
    Recruiting - verified May 2017

  • Condition:   Benzodiazepine Refractory Status Epilepticus
    Interventions:   Drug: Fosphenytoin;   Drug: Levetiracetam;   Drug: Valproic acid
    Sponsors:   University of Virginia;   University of Michigan;   Medical University of South Carolina;   Children's Research Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting - verified May 2017

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: fulvestrant;   Drug: anastrozole
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Recurrent Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Baricitinib;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified May 2017

  • Conditions:   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Erlotinib Hydrochloride;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   American College of Radiology Imaging Network
    Recruiting - verified May 2017

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   HER2 Positive Breast Carcinoma;   Invasive Breast Carcinoma;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Radiation: Stereotactic Radiosurgery;   Radiation: Whole-Brain Radiotherapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVA Vulvar Cancer;   Vulvar Squamous Cell Carcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Stage I Uterine Sarcoma;   Uterine Corpus Leiomyosarcoma
    Interventions:   Other: Clinical Observation;   Drug: Docetaxel;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Drug: Gemcitabine Hydrochloride;   Biological: Pegfilgrastim
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Solid Tumors;   Primary Brain Tumors
    Interventions:   Drug: Vincristine;   Drug: Irinotecan;   Drug: Temozolomide;   Drug: Metformin
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Pediatric Cancer Foundation
    Recruiting - verified May 2017

  • Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Leukemia Cutis;   Myeloid Sarcoma;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Prostate Cancer
    Interventions:   Radiation: radiation therapy;   Radiation: Whole-pelvic radiotherapy (WPRT)
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
    Recruiting - verified May 2017

  • Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting - verified May 2017

  • Conditions:   Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Head and Neck Cancer
    Interventions:   Drug: cisplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
    Recruiting - verified April 2017

  • Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Lymphoma
    Interventions:   Drug: ABVD;   Drug: BEACOPP;   Radiation: radiation therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Capecitabine;   Drug: Chemotherapy;   Drug: Erlotinib Hydrochloride;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
    Interventions:   Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Head and Neck Cancer
    Interventions:   Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
    Recruiting - verified May 2017

  • Conditions:   Metastatic Cancer;   Pain
    Interventions:   Radiation: external beam radiation therapy;   Radiation: image-guided radiation therapy;   Radiation: radiosurgery;   Radiation: stereotactic body radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
    Recruiting - verified May 2017

  • Conditions:   Surgery;   Anesthesia;   Children
    Intervention:  
    Sponsors:   The Society for Pediatric Anesthesia;   Children's Hospital Medical Center, Cincinnati;   Monroe Carell Jr. Children's Hospital at Vanderbilt;   Seattle Children's Hospital;   Boston Children’s Hospital;   Emory-Children's Center;   Texas Children's Hospital;   Johns Hopkins University;   Children's Hospital Los Angeles;   Morgan Stanley Children's Hospital of New York;   Children's Hospital of Philadelphia;   Ann & Robert H Lurie Children's Hospital of Chicago;   Children's Hospital of Pittsburgh;   Phoenix Children's Hospital;   University of Michigan;   Children's National Health System;   Nationwide Children's Hospital;   Arkansas Children's Hospital Research Institute;   Children's Hospital Colorado;   St. Jude Children's Research Hospital;   Cook Children's Health Care System;   SSM Cardinal Glennon Children's Medical Center;   The Children's Hospital at Montefiore;   Children's Medical Center Dallas;   Lucile Packard Children's Hospital Stanford;   Alfred I. duPont Hospital for Children;   Johns Hopkins All Children's Hospital;   Children's Hospitals and Clinics of Minnesota;   Oakland Medical Center;   Children's Hospital and Medical Center, Omaha;   Medical University of South Carolina;   Akron Children's Hospital;   Women & Children's Hospital of Buffalo
    Recruiting - verified May 2017

  • Conditions:   Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2017